zonisamide has been researched along with Pregnancy in 16 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animal data suggest teratogenic effects with zonisamide use and risk of pregnancy losses." | 8.02 | Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. ( Bromley, R; Campbell, E; Craig, JJ; Delanty, N; Heath, C; Hunt, SJ; Irwin, B; Kinney, MO; Liggan, B; MacKillop, L; McCluskey, G; Morrison, PJ; Morrow, J; Murphy, S; Parsons, L; Russell, A; Smithson, WH, 2021) |
| "To investigate the change in zonisamide (ZNS) serum concentration and its consequences in pregnant women with epilepsy." | 7.88 | Zonisamide serum concentrations during pregnancy. ( Aurlien, D; Becser Andersen, N; Brodtkorb, E; Christensen, J; Haggag, K; Helde, G; Lillestølen, KM; Nakken, KO; Reimers, A; Surlien Navjord, E, 2018) |
| "To assess the possible effects of topiramate and zonisamide use during pregnancy on fetal growth." | 7.80 | Association between topiramate and zonisamide use during pregnancy and low birth weight. ( Hauser, WA; Hernández-Díaz, S; Holmes, LB; Mittendorf, R; Smith, CR; Yerby, M, 2014) |
| "A 30-year-old woman with primary generalized tonic-clonic seizures and myoclonic jerks was taking zonisamide 200 mg daily as her sole antiepileptic agent when she conceived." | 7.74 | Zonisamide concentrations during pregnancy. ( Bell, WL; Oles, KS, 2008) |
| "Pregnancy is a state where drug pharmacokinetic changes are more pronounced and more rapid than any other period of life." | 5.48 | Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats. ( Keramati, K; Mahdavi, A; Moezifar, M; Narenji Sani, R; Saberi, N, 2018) |
| " The present study was aimed to investigate the potential effects of pregnancy on the pharmacokinetic profile of zonisamide (ZNM) in the rabbit." | 5.39 | Impact of pregnancy on zonisamide pharmacokinetics in rabbits. ( Matar, KM, 2013) |
| "Anencephaly was detected in one case at 16 weeks of gestation (case 1, artificial abortion), and atrial septal defect was detected in another case at 37 weeks of gestation (case 2, delivery by cesarean section)." | 5.29 | Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. ( Amano, Y; Egawa, I; Kaneko, S; Kondo, T, 1996) |
| "A brief review of epilepsy as a disease, anti-epileptic drugs and methods of evaluation of anti-epileptic drugs are presented as a background for assessment of zonisamide, which has been approved by the FDA as add-on therapy for the treatment of partial seizures with or without secondary generalisation in adults." | 4.80 | An assessment of zonisamide as an anti-epileptic drug. ( Jain, KK, 2000) |
| "05) of an increased hazard of fetal malformation associated with exposure to valproate, carbamazepine, topiramate, zonisamide, and with conception after assisted fertilization, but a reduced hazard in the offspring of women who continued to smoke during pregnancy." | 4.31 | Specific fetal malformations following intrauterine exposure to antiseizure medication. ( Eadie, M; Graham, J; Hitchcock, A; Lander, C; O'Brien, T; Perucca, P; Vajda, F, 2023) |
| "Animal data suggest teratogenic effects with zonisamide use and risk of pregnancy losses." | 4.02 | Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register. ( Bromley, R; Campbell, E; Craig, JJ; Delanty, N; Heath, C; Hunt, SJ; Irwin, B; Kinney, MO; Liggan, B; MacKillop, L; McCluskey, G; Morrison, PJ; Morrow, J; Murphy, S; Parsons, L; Russell, A; Smithson, WH, 2021) |
| "To investigate the change in zonisamide (ZNS) serum concentration and its consequences in pregnant women with epilepsy." | 3.88 | Zonisamide serum concentrations during pregnancy. ( Aurlien, D; Becser Andersen, N; Brodtkorb, E; Christensen, J; Haggag, K; Helde, G; Lillestølen, KM; Nakken, KO; Reimers, A; Surlien Navjord, E, 2018) |
| "To assess the possible effects of topiramate and zonisamide use during pregnancy on fetal growth." | 3.80 | Association between topiramate and zonisamide use during pregnancy and low birth weight. ( Hauser, WA; Hernández-Díaz, S; Holmes, LB; Mittendorf, R; Smith, CR; Yerby, M, 2014) |
| "A 30-year-old woman with primary generalized tonic-clonic seizures and myoclonic jerks was taking zonisamide 200 mg daily as her sole antiepileptic agent when she conceived." | 3.74 | Zonisamide concentrations during pregnancy. ( Bell, WL; Oles, KS, 2008) |
| "Zonisamide is widely used for intractable epilepsy and the effects of this drug on fetuses and neonates through the mother taking it for epilepsy need to be clarified." | 3.71 | Pharmacokinetics of zonisamide in perinatal period. ( Ishii, M; Isobe, K; Itoh, S; Kawada, K; Kusaka, T, 2002) |
| " Exposure to certain newer ASMs, such as lamotrigine and levetiracetam, does not thus far appear to impact certain aspects of neurodevelopment, but further delineation across the different neurodevelopmental domains and dosage levels is required." | 2.72 | Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review. ( Bromley, RL; Knight, R; Wittkowski, A, 2021) |
| "Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures." | 2.45 | The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? ( Abou-Khalil, B; Montouris, G, 2009) |
| "Pregnancy is a state where drug pharmacokinetic changes are more pronounced and more rapid than any other period of life." | 1.48 | Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats. ( Keramati, K; Mahdavi, A; Moezifar, M; Narenji Sani, R; Saberi, N, 2018) |
| " The present study was aimed to investigate the potential effects of pregnancy on the pharmacokinetic profile of zonisamide (ZNM) in the rabbit." | 1.39 | Impact of pregnancy on zonisamide pharmacokinetics in rabbits. ( Matar, KM, 2013) |
| "The etiology of Moebius syndrome remains unknown." | 1.34 | A case of Moebius syndrome presenting with congenital bilateral vocal cord paralysis. ( Arinami, T; Hasegawa, M; Kamoda, T; Kanemoto, K; Kanemoto, N, 2007) |
| "Anencephaly was detected in one case at 16 weeks of gestation (case 1, artificial abortion), and atrial septal defect was detected in another case at 37 weeks of gestation (case 2, delivery by cesarean section)." | 1.29 | Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. ( Amano, Y; Egawa, I; Kaneko, S; Kondo, T, 1996) |
| " [14C]AD-810 was found to be completely absorbed from digestive tracts in animals, since urinary and biliary excretion accounted for virtually total recovery of dosed radioactivity." | 1.27 | Absorption, distribution and excretion of 3-(sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in Rats, Dogs and Monkeys and of AD-810 in Men. ( Fujii, T; Hashimoto, M; Kagemoto, A; Maeda, T; Matsumoto, K; Miyazaki, H, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pennell, PB | 1 |
| Karanam, A | 1 |
| Meador, KJ | 1 |
| Gerard, E | 1 |
| Kalayjian, L | 1 |
| Penovich, P | 1 |
| Matthews, A | 1 |
| McElrath, TM | 1 |
| Birnbaum, AK | 1 |
| Vajda, F | 1 |
| O'Brien, T | 1 |
| Graham, J | 1 |
| Hitchcock, A | 1 |
| Perucca, P | 1 |
| Lander, C | 1 |
| Eadie, M | 1 |
| Knight, R | 1 |
| Wittkowski, A | 1 |
| Bromley, RL | 1 |
| McCluskey, G | 1 |
| Kinney, MO | 1 |
| Russell, A | 1 |
| Smithson, WH | 1 |
| Parsons, L | 1 |
| Morrison, PJ | 1 |
| Bromley, R | 1 |
| MacKillop, L | 1 |
| Heath, C | 1 |
| Liggan, B | 1 |
| Murphy, S | 1 |
| Delanty, N | 1 |
| Irwin, B | 1 |
| Campbell, E | 1 |
| Morrow, J | 1 |
| Hunt, SJ | 1 |
| Craig, JJ | 1 |
| Narenji Sani, R | 1 |
| Keramati, K | 1 |
| Saberi, N | 1 |
| Moezifar, M | 1 |
| Mahdavi, A | 1 |
| Reimers, A | 1 |
| Helde, G | 1 |
| Becser Andersen, N | 1 |
| Aurlien, D | 1 |
| Surlien Navjord, E | 1 |
| Haggag, K | 1 |
| Christensen, J | 1 |
| Lillestølen, KM | 1 |
| Nakken, KO | 1 |
| Brodtkorb, E | 1 |
| Matar, KM | 1 |
| Hernández-Díaz, S | 1 |
| Mittendorf, R | 1 |
| Smith, CR | 1 |
| Hauser, WA | 1 |
| Yerby, M | 1 |
| Holmes, LB | 1 |
| Oles, KS | 1 |
| Bell, WL | 1 |
| Montouris, G | 1 |
| Abou-Khalil, B | 1 |
| Terada, K | 1 |
| Inoue, Y | 1 |
| Kanemoto, N | 1 |
| Kanemoto, K | 1 |
| Kamoda, T | 1 |
| Hasegawa, M | 1 |
| Arinami, T | 1 |
| Matsumoto, K | 1 |
| Miyazaki, H | 1 |
| Fujii, T | 1 |
| Kagemoto, A | 1 |
| Maeda, T | 1 |
| Hashimoto, M | 1 |
| Kondo, T | 1 |
| Kaneko, S | 1 |
| Amano, Y | 1 |
| Egawa, I | 1 |
| Jain, KK | 1 |
| Kawada, K | 1 |
| Itoh, S | 1 |
| Kusaka, T | 1 |
| Isobe, K | 1 |
| Ishii, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physiological-based Pharmacokinetics Approach to Determine the Extent of Drug Exposure of Antiseizure Medications During Pregnancy and Breastfeeding[NCT05450978] | 60 participants (Anticipated) | Observational [Patient Registry] | 2022-07-20 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for zonisamide and Pregnancy
| Article | Year |
|---|---|
Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review.
Topics: Anticonvulsants; Child; Female; Gabapentin; Humans; Lacosamide; Lamotrigine; Levetiracetam; Oxcarbaz | 2021 |
The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Topics: Anticonvulsants; Congenital Abnormalities; Delayed-Action Preparations; Drug Design; Epilepsy, Gener | 2009 |
An assessment of zonisamide as an anti-epileptic drug.
Topics: Adolescent; Adult; Aged; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Female | 2000 |
13 other studies available for zonisamide and Pregnancy
| Article | Year |
|---|---|
Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lacosamide; Lamotrigine; Levetirace | 2022 |
Specific fetal malformations following intrauterine exposure to antiseizure medication.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Carbamazepine; Female; Humans; Male; Pregna | 2023 |
Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Ireland; | 2021 |
Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Brain; Drug Resistance; Drug Resistant Epilepsy; Female; | 2018 |
Zonisamide serum concentrations during pregnancy.
Topics: Adult; Denmark; Drug Monitoring; Epilepsy; Female; Gestational Age; Humans; Norway; Pregnancy; Pregn | 2018 |
Impact of pregnancy on zonisamide pharmacokinetics in rabbits.
Topics: Administration, Oral; Animals; Anticonvulsants; Epilepsy; Female; Humans; Isoxazoles; Pregnancy; Rab | 2013 |
Association between topiramate and zonisamide use during pregnancy and low birth weight.
Topics: Adult; Anticonvulsants; Birth Weight; Cohort Studies; Female; Fructose; Humans; Isoxazoles; Pregnanc | 2014 |
Zonisamide concentrations during pregnancy.
Topics: Adult; Anticonvulsants; Female; Humans; Isoxazoles; Myoclonic Epilepsy, Juvenile; Pregnancy; Pregnan | 2008 |
[Clinical application of newer anti-epileptic drugs].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; gamma- | 2012 |
A case of Moebius syndrome presenting with congenital bilateral vocal cord paralysis.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Isoxazoles; Mobius Syndrome; Pregnancy; | 2007 |
Absorption, distribution and excretion of 3-(sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in Rats, Dogs and Monkeys and of AD-810 in Men.
Topics: Animals; Autoradiography; Bile; Dogs; Erythrocytes; Female; Humans; Intestinal Absorption; Isoxazole | 1983 |
Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anencephaly; Anticonvulsants; Epilepsy; Female; Humans; Infant, | 1996 |
Pharmacokinetics of zonisamide in perinatal period.
Topics: Adult; Anticonvulsants; Chromatography, High Pressure Liquid; Epilepsy; Female; Fetal Blood; Humans; | 2002 |